Xu, Wenhao
Ye, Shiqi
Liu, Wangrui
Guo, Huaqi
Zhang, Linhui
Wei, Shiyin
Anwaier, Aihetaimujiang
Chang, Kun
Malafaia, Guilherme
Zhang, Hailiang
Ye, Dingwei
Wei, Gang
Funding for this research was provided by:
Shanghai Anti-Cancer Association Eyas Project (SACA-CY21A06, SACA-CY21B01)
National Natural Science Foundation of China (82370847, 82370847)
National Council for Scientific and Technological Development (308854/2021-7)
Natural Science Foundation of Shanghai (20ZR1413100)
Beijing Xisike Clinical Oncology Research Foundation (Y-HR2020MS-0948)
Shanghai Municipal Health Bureau Project (2020CXJQ03)
Article History
Received: 31 August 2023
Accepted: 12 December 2023
First Online: 3 January 2024
Declarations
:
: The study design and test procedures followed the Helsinki Declaration II. The Ethics approval and consent to participate of the Urology and Pathology departments in this study were approved by the Fudan University Shanghai Cancer Center Institutional Review Board (IRB) (No: 050432-4-2108*, FUSCC, Shanghai, China). Our in vivo research complies with all relevant ethical regulations. Ethical review approval (FUSCC-IACUC-S2022-0626, FUSCC, Shanghai, China) was obtained from the Institutional Animal Care and Use Committee (IACUC), FUSCC. All animal procedures were performed in accordance with the guidelines of IACUC, FUSCC.
: The authors declare no competing interests.